|
GSK PLC on Monday said a US court has dismissed part of a legal claim involving its subsidiary Tesaro Inc. Tesaro is a US arm of London-based drugmaker GSK that focuses on cancer treatment. Tesaro took AnaptysBio Inc to court after AnaptysBio alleged that Tesaro had failed to fulfil requirements of a licence agreement dating back to March 2014. As a result, AnaptysBio said it planned to revoke the licence. ‘GSK and Tesaro are firmly of the view that these allegations are entirely without merit and remain focused on pursuing that claim at trial,’ GSK said on Monday. The licence covers dostarlimab, marketed as Jemperli, which is approved as an endometrial cancer therapy in 35 countries, according to GSK. The Delaware Chancery Court has granted a motion to dismiss filed by AnaptysBio against Tesaro’s claim for anticipatory breach. GSK stressed that this ruling ‘does not address the merits of the principal contractual dispute’ and will not impact Tesaro’s remaining claim against AnaptysBio for declaratory judgement. Earlier this month, GSK updated on another drug in its endometrial cancer portfolio, mocertatug rezetecan, which also targets ovarian cancer. GSK had noted positive trial data for mocertatug rezetecan, which it has licensed from Hansoh Pharmaceutical Group Co Ltd. GSK shares were up 0.1% to 2,021.00 pence early Monday morning in London. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
